AIMS: Completion lymph node dissection (CLND) and adjuvant therapy are recommended for node-positive melanoma patients. We sought to analyze our institution's experience with neoadjuvant biochemotherapy in stage III patients. METHODS: Clinical information was extracted from a retrospective database on stage III melanoma patients. Eligible patients received two cycles of biochemotherapy prior to their CLND. RESULTS: There were 153 patients available for analysis. The average tumor depth was 2.5 mm. More than half of all patients presented with sentinel lymph node-positive disease. Surgical complications occurred in 23% of patients. Patients who experienced an adverse event during their neoadjuvant therapy had a worse overall survival when compared with those who did not (p = 0.005). CONCLUSION: Our data suggest that aggressive neoadjuvant treatment prior to CLND does not impact surgical complications. Our surgical outcomes are similar to the current literature when adjuvant therapy is used in stage III melanoma. The inability to tolerate neoadjuvant therapy in stage III melanoma is a negative prognostic indicator.
AIMS: Completion lymph node dissection (CLND) and adjuvant therapy are recommended for node-positive melanomapatients. We sought to analyze our institution's experience with neoadjuvant biochemotherapy in stage III patients. METHODS: Clinical information was extracted from a retrospective database on stage III melanomapatients. Eligible patients received two cycles of biochemotherapy prior to their CLND. RESULTS: There were 153 patients available for analysis. The average tumor depth was 2.5 mm. More than half of all patients presented with sentinel lymph node-positive disease. Surgical complications occurred in 23% of patients. Patients who experienced an adverse event during their neoadjuvant therapy had a worse overall survival when compared with those who did not (p = 0.005). CONCLUSION: Our data suggest that aggressive neoadjuvant treatment prior to CLND does not impact surgical complications. Our surgical outcomes are similar to the current literature when adjuvant therapy is used in stage III melanoma. The inability to tolerate neoadjuvant therapy in stage III melanoma is a negative prognostic indicator.
Authors: F Stephen Hodi; Philip Friedlander; Christopher L Corless; Michael C Heinrich; Suzanne Mac Rae; Andrea Kruse; Jyothi Jagannathan; Annick D Van den Abbeele; Elsa F Velazquez; George D Demetri; David E Fisher Journal: J Clin Oncol Date: 2008-04-20 Impact factor: 44.544
Authors: Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak Journal: J Clin Oncol Date: 2010-04-05 Impact factor: 44.544
Authors: Alessandro Testori; Gian Luca De Salvo; Maria Cristina Montesco; Giuseppe Trifirò; Simone Mocellin; Giorgio Landi; Giuseppe Macripò; Paolo Carcoforo; Giuseppe Ricotti; Giuseppe Giudice; Franco Picciotto; Davide Donner; Franco Di Filippo; Javier Soteldo; Dario Casara; Mauro Schiavon; Antonella Vecchiato; Sandro Pasquali; Federica Baldini; Giovanni Mazzarol; Carlo Riccardo Rossi Journal: Ann Surg Oncol Date: 2009-01-09 Impact factor: 5.344
Authors: Kevin B Kim; Sewa S Legha; Rene Gonzalez; Clay M Anderson; Marcella M Johnson; Ping Liu; Nicholas E Papadopoulos; Omar Eton; Carl Plager; Antonio C Buzaid; Victor G Prieto; Wen-Jen Hwu; Angela M Frost; Gladys Alvarado; Patrick Hwu; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Robert S Benjamin; Agop Y Bedikian Journal: Melanoma Res Date: 2009-02 Impact factor: 3.599
Authors: Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma Journal: Clin Cancer Res Date: 2010-05-11 Impact factor: 12.531
Authors: Zeynep Eroglu; Jennifer Eatrides; Syeda Mahrukh Hussnain Naqvi; Youngchul Kim; Jeani Rich; Nalan Akgul Babacan; Andrew S Brohl; Joseph Markowitz; Amod Sarnaik; Jonathan Zager; Nikhil I Khushalani; Vernon K Sondak; Jane Messina Journal: Pigment Cell Melanoma Res Date: 2019-09-12 Impact factor: 4.693